Proteogenomic analysis reveals exosomes are more oncogenic than ectosomes
Metrics: PDF 2954 views | HTML 5983 views | ?
Shivakumar Keerthikumar1,*, Lahiru Gangoda1,*, Michael Liem1, Pamali Fonseka1, Ishara Atukorala1, Cemil Ozcitti1, Adam Mechler2, Christopher G. Adda1, Ching-Seng Ang3 and Suresh Mathivanan1
1 Department of Biochemistry, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria, Australia
2 Department of Chemistry, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria, Australia
3 Bio21 Institute, University of Melbourne, Victoria, Australia
* These authors have contributed equally to this work
Suresh Mathivanan, email:
Keywords: exosomes, ectosomes, proteogenomics, extracellular vesicles, integrated OMICs analysis
Received: January 27, 2015 Accepted: March 18, 2015 Published: April 12, 2015
Extracellular vesicles (EVs) include the exosomes (30-100 nm) that are produced through the endocytic pathway via the multivesicular bodies and the ectosomes (100-1000 nm) that are released through the budding of the plasma membrane. Despite the differences in the mode of biogenesis and size, reliable markers that can distinguish between exosomes and ectosomes are non-existent. Moreover, the precise functional differences between exosomes and ectosomes remains poorly characterised. Here, using label-free quantitative proteomics, we highlight proteins that could be exploited as markers to discriminate between exosomes and ectosomes. For the first time, a global proteogenomics analysis unveiled the secretion of mutant proteins that are implicated in cancer progression through tumor-derived EVs. Follow up integrated bioinformatics analysis highlighted the enrichment of oncogenic cargo in exosomes and ectosomes. Interestingly, exosomes induced significant cell proliferation and migration in recipient cells compared to ectosomes confirming the oncogenic nature of exosomes. These findings ascertain that cancer cells facilitate oncogenesis by the secretion of mutant and oncoproteins into the tumor microenvironment via exosomes and ectosomes. The integrative proteogenomics approach utilized in this study has the potential to identify disease biomarker candidates which can be later assayed in liquid biopsies obtained from cancer patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.